

RATHER

Rational Therapy for Breast Cancer

6 Academic Partners



2 Collaborating SMEs



4 Clinical Trials underway

> 120 patients recruited



Further Funding Leveraged
€17.9 million



Initial EU Funding
€6 million

4 Patents Filed

1 Prognostic assay validated for ILC



Protein kinases
Improved survival
Clinical trials Patients
Better outcomes Novel
Collaboration
Biomarkers New
Triple Negative Breast Cancer
Therapeutic targets
Companion diagnostics
Invasive Lobular Carcinoma


19 Original Articles

3 Review Articles

85 Presentations




New Discoveries



New biomarkers for TN* and ILC**
New biomarker signatures for TN and ILC
New treatment strategies for TN and ILC

>70 in RATHER team
working over 7.5 years



*TN - Triple Negative Breast Cancer

** ILC - Invasive Lobular Carcinoma